Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clnu.2022.06.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Commentary: Harmane potentiates nicotine reinforcement through MAO-A inhibition at the dose related to cigarette smoking.
Front Mol Neurosci
February 2023
School of Health Sciences, College of Health, Massey University, Wellington, New Zealand.
Comments on "dose-related meta-analysis for omega-3 fatty acids supplementation on major adverse cardiovascular events".
Clin Nutr
August 2022
Second Medical Clinic, School of Medicine, Ippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki 54642, Macedonia, Greece; Division of Gastroenterology and Hepatology, Medical University Department, Kantonsspital Aarau, Aarau 5001, Switzerland.
Are serious ophthalmic adverse events on dupilumab treatment for atopic dermatitis dose related?
Int J Dermatol
October 2022
Dermatology Clinic, Department of Medical Sciences, University of Turin, Turin, Italy.
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Clin Cancer Res
January 2022
Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
Purpose: In this first-in-human study (NCT03564691) in advanced solid tumors, we investigated a novel first-in-class human IgG4 monoclonal antibody targeting the immunoglobulin-like transcript 4 (ILT4) receptor, MK-4830, as monotherapy and in combination with pembrolizumab.
Patients And Methods: Patients with histologically/cytologically confirmed advanced solid tumors, measurable disease by RECIST v1.1, and evaluable baseline tumor sample received escalating doses of intravenous MK-4830 every 3 weeks as monotherapy (parts A and B) and in combination with pembrolizumab (part C).
First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors.
Clin Cancer Res
September 2019
Early Drug Development Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose: STM 434 is a soluble receptor ligand trap targeting activin A, a protein in the TGFβ family that plays important roles in growth, differentiation, and cancer cachexia. This study evaluated the safety, antitumor activity, and metabolic effects of STM 434 in a first-in-human, multicenter, phase I clinical trial (NCT02262455).
Patients And Methods: Patients with advanced solid tumors were enrolled in 8 dose cohorts ranging from 0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!